Get the Stockscreener App
4.41
4.75%
-0.22
After Hours:
4.41
Avalo Therapeutics Inc stock is traded at $4.41, with a volume of 73,888.
It is down -4.75% in the last 24 hours and down -42.65% over the past month.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
See More
Previous Close:
$4.63
Open:
$4.66
24h Volume:
73,888
Relative Volume:
1.02
Market Cap:
$57.42M
Revenue:
$1.93M
Net Income/Loss:
$-7.96M
P/E Ratio:
-0.00125
EPS:
-3530.8178
Net Cash Flow:
$-36.78M
1W Performance:
-10.73%
1M Performance:
-42.65%
6M Performance:
-57.60%
1Y Performance:
-67.62%
1-Day Range:
$4.31
$4.9467
1-Week Range:
$4.31
$5.85
52-Week Range:
$4.31
$17.49
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
540 GAITHER ROAD, ROCKVILLE
Compare AVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
4.41 | 57.42M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
Avalo Therapeutics (AVTX) Sees New Options Listings for April | - GuruFocus
Seven new option listings and one option delisting on April 16th - TipRanks
Avalo Therapeutics Reports 2024 Financial Results - TipRanks
(AVTX) On The My Stocks Page - news.stocktradersdaily.com
AVTX stock touches 52-week low at $5.98 amid market challenges - Investing.com Australia
AVTX stock touches 52-week low at $5.98 amid market challenges By Investing.com - Investing.com South Africa
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at Stifel Nicolaus - MarketBeat
Avalo Therapeutics (AVTX) to Release Earnings on Friday - Defense World
Analysts Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $33.00 - Defense World
Avalo Therapeutics names new Chairman amid growth phase By Investing.com - Investing.com South Africa
Avalo Therapeutics Names Michael Heffernan as Board Chairman - MarketScreener
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board - GlobeNewswire
Avalo Therapeutics Appoints Michael Heffernan As Chairman Of The Board - MarketScreener
Avalo Therapeutics names new Chairman amid growth phase - Investing.com
DynaCERT And Avalo Therapeutics Poised For Growth - Evrim Ağacı
Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Analysts at Stifel Nicolaus - Defense World
Stifel initiates Avalo Therapeutics stock with a Buy rating By Investing.com - Investing.com Australia
Jefferies Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation - Nasdaq
Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside - Benzinga
Jefferies starts Avalo stock with Buy, sets $23 price target By Investing.com - Investing.com Australia
This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Stifel Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation - Nasdaq
Stifel Initiates Avalo Therapeutics at Buy With $36 Price Target - MarketScreener
How the (AVTX) price action is used to our Advantage - news.stocktradersdaily.com
Jefferies starts Avalo stock with Buy, sets $23 price target - Investing.com
Stifel initiates Avalo Therapeutics stock with a Buy rating - Investing.com India
Oppenheimer maintains Avalo stock Outperform with $35 target By Investing.com - Investing.com Canada
Oppenheimer maintains Avalo stock Outperform with $35 target - Investing.com
Equities Analysts Set Expectations for AVTX Q1 Earnings - Defense World
Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX) - The Globe and Mail
Wedbush Research Analysts Lift Earnings Estimates for AVTX - Defense World
Wedbush Forecasts Increased Earnings for Avalo Therapeutics - The AM Reporter
HC Wainwright Reiterates Neutral Rating for Avalo Therapeutics (NASDAQ:AVTX) - Defense World
Q1 EPS Estimates for Avalo Therapeutics Boosted by Wedbush - Defense World
Avalo Reports 2024 Financial Results and Recent Business Updates - GlobeNewswire
Avalo Therapeutics Reports Business Updates and Financial Results for 2024, Highlights Phase 2 LOTUS Trial Progress for AVTX-009 in Hidradenitis Suppurativa - Nasdaq
Avalo Therapeutics, Inc. SEC 10-K Report - TradingView
Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Thursday - Defense World
AVTX’s 52-Week Rollercoaster: From $4.35 to $34.46 – What’s Next for Investors? - The InvestChronicle
PSTV Rallies, TOVX Gears Up For VIRAGE Trial Data, Will AVTX's LOTUS Bloom? - RTTNews
(AVTX) Investment Analysis - Stock Traders Daily
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at Piper Sandler - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated by Analysts at Piper Sandler - MarketBeat
Piper Sandler Initiates Coverage of Avalo Therapeutics (AVTX) with Overweight Recommendation - Nasdaq
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga India
Piper Sandler Initiates Avalo Therapeutics at Overweight With $48 Price Target -February 28, 2025 at 07:54 am EST - Marketscreener.com
Piper Sandler sets $48 target on Avalo Therapeutics stock - Investing.com
Avalo Therapeutics (NASDAQ:AVTX) Upgraded by Wedbush to "Strong-Buy" Rating - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Analysts at Wedbush - MarketBeat
Avalo Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avalo Therapeutics Inc Stock (AVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Almenoff June Sherie | Director |
Nov 12 '24 |
Buy |
12.50 |
500 |
6,250 |
500 |
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):